Health ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

Obesity Treatments Lenacapavir Semaglutide Monoclonal Antibodies Efficacy Studies FDA Approval Regulatory Approval Simufilam Innovative Treatments Novo Nordisk Retatrutide Rare Diseases Market Claims ITI-1284 Sodium Channel Blockers Safety Concerns Obeldesivir Cancer Treatments Weight Loss AI in Drug Design Medical Research NTLA-3001 Market Impact Market Approval Antivenom Production Weight-loss Medicines Phase II Trials Baxdrostat FDA-Approved Drugs Human Trials Patient Outcomes AI in Healthcare AbbVie Research and Development Hypertension Treatments Data Protection Safety and Efficacy Obesity Treatment Olezarsen Lipid-Lowering Drugs Investor Impact Pfizer FDA Approvals Tolebrutinib GLP-1 Receptor Agonists Biontech Regulatory Changes Male Contraceptive Trials Market Competition New Medications COVID-19 Vaccines Cancer Treatment UK Healthcare System Diabetes Treatments Autoimmune Disorders Multiple Sclerosis Efzofitimod Therapeutics Methylenomicina A PCSK9 Inhibitors Ganaplacide-Lumefantrine Breast Cancer Treatments Efficacy Claims Phase 3 Trials Antibiotics Wegovy Type 2 Diabetes GLP-1 Drugs Drug Effectiveness Long-acting Injectables Molecular Therapy Regulatory Affairs Postpartum Depression Mental Health Gastroparesis Innovative Therapies Growth Hormone Deficiency Drug Behavior Prediction Drug Simulation Investigational Drugs Weight Loss Drugs

MoonLake Investors Courted by Law Firms as Lead‑Plaintiff Deadline Nears in SDNY Securities Case

The suit stems from September trial data that preceded a near‑90% one‑day drop in MoonLake’s share price.

Sorfequiline Outperforms Standard TB Regimens in Phase 2 Trial

aTyr Securities Suits Intensify as New Filing Expands Class Period Ahead of Dec. 8 Deadline

First New Antimalarial in Decades Tops 97% Cure in Phase III as Novartis Seeks Approval

MoonLake Investors Face Dec. 15 Deadline in Securities Suits Over Sonelokimab Claims

MoonLake Investors Courted for Lead Role in SDNY Securities Case After SLK Trial Collapse

FDA Rejects Biohaven’s Vyglxia for Spinocerebellar Ataxia

MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline in SDNY Securities Case

MoonLake Faces Securities Class Action After SLK Trial Miss as Firms Seek Lead Plaintiff

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

aTyr Faces Securities Suit After Phase 3 Failure Triggers 83% Stock Crash

Biohaven Investors Face Sept. 12 Deadline in Securities Class Action

Tufts Team Designs Experimental Four-Hormone Obesity Drug Aimed at Bigger, Gentler Weight Loss

Ionis’ Olezarsen Slashes Triglycerides, Cuts Pancreatitis in Phase 3 Trials

FDA Approves Papzimeos as First Therapy for Adult Recurrent Respiratory Papillomatosis

AI-Powered Discovery Yields WYS-694, a Broad-Spectrum Coronavirus Antiviral

AI-Designed Rentosertib Improves Lung Function in Phase IIa IPF Trial